NetworkNewsBreaks – Algae Dynamics Corp. (ADYNF) Announces Entry into Letter of Intent with Licensed Cannabis Producer Bonify

Algae Dynamics Corp. (OTCQB: ADYNF), a company focused on the development of unique health products and pharmaceuticals utilizing cannabis and algae oils, this morning announced its entry into a letter of intent with 6779264 Manitoba Ltd dba Bonify, a licensed producer with the capability to grow multiple strains of cannabis in its state-of-the-art 320,000 square foot facility. Under the terms of the agreement, Bonify has agreed to supply raw cannabis plant material to ADYNF for processing into cannabis oil for sale and for use in research. “We believe this Letter of Intent gives us an improved pathway to early revenues as well as a reliable high-quality source of cannabis oil for the universities to support our important algae-cannabis oil research,” Paul Ramsay, chairman and president of ADYNF, stated in the news release. “We look forward to expeditiously completing this agreement.” The term of the agreement is for three years from the commencement of operations and is renewable by mutual agreement. Given the favorable terms of this agreement with Bonify, ADYNF does not anticipate moving forward with its previously announced joint venture with ARA – Avanti Rx Analytics Inc.

To view the full press release, visit http://nnw.fm/xlD9n

About Algae Dynamics Corp.

ADC is engaged in the development of unique health products and pharmaceuticals that utilize hemp, cannabis and algae oils. We have engaged two Canadian universities to provide research into the use of extracts from cannabis oil, which we plan to use to develop products that combine the significant health benefits of Omega-3s derived from algae oil and extracts from cannabis oil. Our research is focused on the use of cannabis oil in the context of cancer, and the use of cannabis derivatives for the development of novel pharmacotherapies for mental health. For more information, visit http://www.algaedynamics.com

More from NetworkNewsBreaks

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

FDA Proposal Puts Spotlight on Big Tobacco and Industry Innovators

NetworkNewsWire Coverage: The black cloud over Big Tobacco has been swirling for decades, but few developments have cast a bigger shadow than the U.S. Food and Drug Administration’s recent proposal to reduce nicotine levels in cigarettes to non-addictive levels. The new plan1, originally unveiled on July 28, is expected to serve as a multi-year roadmap aimed at saving lives and significantly reducing the effects of tobacco-related diseases. The market effects of the nicotine push have proven to be colossal, with shares of two of the largest sellers of cigarettes in the United States suffering their largest single-day plunge since the recession following the announcement. Indeed, the FDA’s sweeping efforts seem to strike a distinctly adversarial tone with the $130 billion U.S. tobacco industry2, presenting an unprecedented opening for companies in position to cash in on the changing market. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) (LXRP Profile), as the only cannabis biotech company that has exposure to nicotine, stands alongside industry mainstays such as Altria Group, Inc. (NYSE: MO), Philip Morris International, Inc. (NYSE: PM) and British American Tobacco p.l.c. (NYSE: BTI), along with upstart 22nd Century Group, Inc. (NYSE: XXII), as the transformation of this global industry accelerates.

The slow death of the once ubiquitous cigarette wasn’t just uncovered with the FDA’s ruling. In fact, Big Tobacco has had its sights set on the development of marketable alternatives to its combustible offerings for years. A quick visit to Philip Morris’ website demonstrates these efforts, as the tagline “Designing a Smoke-Free Future” is placed front-and-center for all to see. As a reminder, Philip Morris is the global cigarette giant behind Marlboro and six of the world’s top 15 international brands, and its tobacco products are currently sold in over 180 countries outside the U.S.

Though still in their relative infancy, smoke-free cigarette alternatives have already proven to be highly marketable as cigarettes and similar products have faced increasing regulations and slumping sales. Per a report3 from the Centers for Disease Control and Prevention, roughly 9 million adult consumers, or 3.7 percent of American adults, used tobacco-free electronic cigarettes or vapor products on a regular basis in 2014. These products typically serve as a delivery method for nicotine, and the National Institute on Drug Abuse4 reports that they are often used to lower nicotine cravings for those who are trying to quit smoking. However, as the Institute notes, there is currently no conclusive scientific evidence on the effectiveness of e-cigarettes for long-term smoking cessation, and, perhaps more importantly, the safety characteristics of these devices haven’t been thoroughly evaluated in independent scientific studies.

A dearth of safe alternatives and an increasingly regulated tobacco industry combine to create a large and rapidly expanding market for smoking cessation solutions. According to a 2016 report5 by Grand View Research, Inc., the global smoking cessation and nicotine de-addiction market is expected to reach over $21.8 billion by 2024. As Grand View reports, “The launch of… improved and innovative nicotine replacement therapy products is to serve as a high impact rendering driver for the growth of the smoking cessation and nicotine de-addiction market.” Staring at a fertile market that’s concentrated on driving innovation, Lexaria Bioscience Corp. (LXRP), with its patented lipid-delivery technology, could prove to be a long-term player offering vast positive community health benefits and considerable upside, particularly for early investors.

Lexaria Bioscience’s intellectual property portfolio features a collection of advancements focused on improving the delivery and absorption of targeted molecules – such as nicotine – to the human body. Notably, the company maintains a patented method by which it is able to infuse a cocktail of molecules that are otherwise difficult for the body to absorb within other ingredients at a molecular level. As Lexaria’s website outlines, the company’s platform allows for the infusion of beneficial hemp oil ingredients into easily-absorbed lipids, greatly increasing the efficiency of absorption. Currently implemented in the production of two distinct consumer product brands including ViPova™ and Lexaria Energy, this technology has proven to be a potential game changer in the cannabinoid-based pharmaceuticals market, an industry that’s on course to grow to $50 billion by 2029, per data aggregated by Statista6.

An equally promising application of this technology relates to the delivery of nicotine, which is also referenced in Lexaria’s lipid-based delivery patent. The company’s proprietary platform allows for the infusion of nicotine molecules within a wide range of edible food ingredients or typical capsule formats, effectively opening the door for the creation of a new product category targeting the high-demand smoking cessation market. Edible or encapsulated forms of nicotine delivery have traditionally failed due to challenges that Lexaria’s new technology may overcome. As the company notes, most of the adverse health outcomes associated with nicotine consumption are due to problematic delivery methods, such as cigarettes and other combustible products. As such, the development of nicotine-infused edible products that remove those dangerous side effects could greatly improve upon the safety profile of most currently-marketed options.

Though promising, Lexaria’s patented molecular delivery technology remains in its early stages. The company is currently investigating the best methods of maximizing on the platform’s market potential. As part of these efforts, Lexaria is also examining the feasibility of in-vitro and in vivo laboratory tests of its technology in order to generate real data regarding the bioavailability of nicotine with and without its protective technology. Combined with potential market indications in the delivery of non-steroidal anti-inflammatories (NSAIDs) and vitamins, markets valued at $5.4 billion and $68 billion respectively, Lexaria’s lipid-delivery technology makes the company an intriguing option for investors with a finger on the pulse of the evolving tobacco industry.

While Lexaria focuses on the development of new delivery technologies for nicotine, much of Big Tobacco has already turned its attention toward the development of reduced-risk alternatives to combustible products. On its website, Altria Group, Inc. (MO), parent company of Philip Morris USA and cigar-maker John Middleton Co., among others, notes that its goals are to develop lower-risk tobacco products for adult consumers, support programs that help reduce underage tobacco use and provide access to expert quitting information for those who have decided to quit. For Altria and many other tobacco industry leaders, much of the focus remains on electronic cigarettes and e-vapor products.

This interest in the electronic cigarette market has seen a lot of early success, though, as noted in an April 2016 report7 from the Royal College of Physicians, “[I]t is not possible to estimate the long-term health risk associated with e-cigarettes precisely.” In 2015, sales of e-cigarettes totaled $2.88 billion, according to Statistic Brain8, up from just $20 million in 2008.

A former operating company of Altria Group, Philip Morris International, Inc. (PM) was spun off in 2008 in an effort to better pursue sales growth in emerging markets. Philip Morris’ most extensive project in the cigarette-alternative space is iQOS (I-Quit-Ordinary-Smoking), which it originally announced in 2014 and currently markets under the Marlboro and Parliament brands. Rather than burning tobacco, the iQOS employs heat to generate a tobacco-based aerosol containing nicotine. As of the end of 2016, Philip Morris’ iQOS was available in over 20 countries, with the company teaming with Altria Group to bring the product to the U.S. in the coming months. Although iQOS and similar heat-not-burn tobacco products present some benefits over cigarettes, such as leaving less smell and odor on clothing, independent research is not currently available to support claims of lowered risk or health benefits, according to the World Health Organization.

British American Tobacco p.l.c. (BTI) categorizes its efforts outside of the traditional tobacco space as “Next Generation Products,” a classification that includes an assortment of alternative tobacco and nicotine products aimed at reducing the risks associated with smoking conventional cigarettes. Per its website, British American Tobacco, over the past five years, has invested more than $1 billion in building its Next Generation Products business. In 2013, it became the first international tobacco company to launch an e-cigarette product in the UK. Since launching its Vype product line, British American Tobacco has introduced products such as the Vype ePen, eTank and eBox, as well as iFuse and glo, two tobacco heating products similar to those offered by Philip Morris.

As with many of its competitors, 22nd Century Group, Inc. (XXII) is focused on reducing the harm caused by smoking, as is communicated through a tagline on its website. Unlike many of its competitors, however, 22nd Century’s products are taking direct aim at the FDA’s latest proposal. As noted in a recent Bloomberg article9, this relatively obscure biotechnology company in western New York grows tobacco plants with just three percent of the nicotine found in typical tobacco plants. Using these plants, the company creates Very Low Nicotine cigarettes that are expected to go through the FDA-approval process as a prescription smoking cessation aid. This innovative approach which, like that of Lexaria Bioscience Corp., goes against the grain in an industry filled to the brim with e-cigarettes and vaping products, has already started to pay off for 22nd Century investors. While Big Tobacco stocks plunged following the FDA’s nicotine announcement, 22nd Century’s shares were up 70 percent for the week ended August 4, including a 25 percent increase on Friday that marked its biggest one-day spike since March 2015.

Where there’s smoke, there’s fire, and Big Tobacco’s industry-wide commitment to developing pioneering devices in the face of increasingly stringent FDA regulations is impossible to overlook. Still, electronic cigarette alternatives and heat-not-burn tobacco products could be half measures in a market that’s primed for a major overhaul. Look for true innovators like Lexaria Bioscience Corp., with its patented lipid-based delivery technology, to develop a foothold as the next iteration of the global $600 billion tobacco industry begins to take shape.

NNW Editorial Sources:
1) FDA http://nnw.fm/2SUkk
2) Bloomberg http://nnw.fm/qQZ00
3) CDC http://nnw.fm/7mXiJ
4) NIDA http://nnw.fm/bM5vN
5) Grandview Research http://nnw.fm/Ytnr1
6) Statista http://nnw.fm/D7L1i
7) Royal College of Physicians http://nnw.fm/kfD16
8) Statistic Brain http://nnw.fm/j4JD4
9) Bloomberg http://nnw.fm/bvH0s

For more information on Lexaria Bioscience please visit: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertake no obligation to update such statements.

Investors Eye Sweet Spots in Canada’s Booming Cannabis Market

NetworkNewsWire Editorial Coverage: Canada is the mecca of the North American cannabis market, boasting legalization in every province and an array of investment opportunities, such as ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF), a Canadian grower of medical marijuana. ABcann recently acquired ABcann Medicinals and boasts a recent IPO, appointment of a new medical consultant, and major expansion plans. As one of Canada’s most dominant growers of medical marijuana and one of the growers to meet the Canadian government’s stringent licensing requirements, ABcann could be positioned to see the post-IPO success achieved by Supreme Pharmaceuticals, Inc. (OTC: SPRWF) (TSX.V: FIRE), Emblem Corp. (OTC: EMMBF) (TSX.V: EMC), Canopy Growth (OTC: TWMJF) (TSX: WEED) and Aurora Cannabis (OTC: ACBFF) – all of which showcased astounding post-IPO gains in the favorable North American cannabis sector.

Ontario-based ABcann Global made its debut on the public market in May 2017 with an IPO priced at $0.80 per share and ambitious plans to foster domestic production facilities and international opportunities. PI Financial analyst Jason Zandberg was quick to initiate coverage of ABcann with a one-year price target of $2.25, which, as of August 15, represents a 160% premium over the company’s stock price of $0.68.

Despite its relative infancy as a publicly traded security, ABcann is one Canada’s dominant medical growers, recognized for using proprietary growing technology to produce organically grown, pesticide-free medicinal-grade marijuana.

The company’s low current market cap offers an obvious opportunity for investors, as ABcann compares well with other companies in an industry that Arcview Market Research expects to top $20 billion by 2021 (http://nnw.fm/4oqBD).

A look at some of ABcann’s peers demonstrates the potential of this market. Among them is Supreme Pharmaceuticals, which soared more than 1,600% after its IPO and currently trades at $0.87 per share. As of August 15, Supreme’s market cap is $250 million. Another Canadian cannabis play, Emblem Corp., has the same size growing facility as ABcann and is valued at $200 million, trading at $1.45 per share. Aurora Cannabis, which surged nearly 900% after its initial offering, trading at $1.97, is valued at $723 million.

Canopy Growth, one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700% in the months following its IPO. As the heavyweight of the group, Canopy is trading at $6.94 per share with a market cap of $1.17 billion.

As noted by analyst Zandberg, part of ABcann’s potential for such a performance is its ability to achieve high yields of its medicinal-grade marijuana through a scalable, computer-controlled growing environment that enables monitoring and control to ensure optimal plant growth while avoiding disease and other plight. ABcann’s expansion plans are ramping up, and a new chamber is planned for the company’s current facility in Napanee, Ontario, which currently produces 1,000 kilograms annually.

The sweet spot of ABcann’s growing position is that it owns the land to be occupied by a new 71,000-square-foot facility with a production capacity of 20,000 kilograms per year – 20 times ABcann’s current production. In further plans, a 65-acre property for a planned 1.2 million square-foot growing facility is ready for development.

Additionally, ABcann was one of the first companies to obtain a production license under Canadian Marijuana for Medical Purposes Regulation, putting it among only 3% of companies that make it through the extensive six-step application process, which requires a comprehensive background check and prior investment in a growing facility.

In July, ABcann announced its inclusion in the Horizons Medical Marijuana Life Sciences ETF (TSX: HMMJ). The ETF index selects companies with operations in biopharmaceuticals, medical manufacturing, distribution, and other marijuana industry services.

Though ABcann as a public company is only three months old, it occupies a unique position with $43 million in cash to fulfill its expansion plans. Earlier this month, as part of a $30 million financing, Cannabis Wheaton Income Corp. made an initial $15 million investment in ABcann to fund additional build-out at the company’s second production facility. The remaining $15 million will fund an additional production expansion with ABcann. Notably, Cannabis Wheaton’s valuation of ABcann matches Zandberg’s price target of $2.25 per ABcann share.

For more information on ABcann Global please visit: ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF)

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with NNW or any company mentioned herein. The commentary, views and opinions expressed in this release by NNW are solely those of NNW and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW and FNM for any investment decisions by their readers or subscribers. NNW and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW and FNM undertake no obligation to update such statements.

Cogint, Inc.’s (NASDAQ: COGT) Sales Jump 29% to $53 Million For 2Q2017

  • Adjusted EBITDA increases 54% in quarter to $4.8 million
  • Cogint’s information services segment revenues rose 39% in quarter
  • Pay Per Call, a new product, generated $1.5 million in additional sales in 2Q2017, as wide range of ‘vertical’ clients adopted it

Cogint, Inc. (NASDAQ: COGT) revenues reached $53 million for the second quarter ended June 30, 2017, a 29% rise as compared to the same period in 2016. Sales for the first half of 2017 ended the same date increased to $103.8 million, also a 29% spike from the prior year, the company announced (http://nnw.fm/L6Int).

Cogint is a cloud-based data analytics company with proprietary algorithm technology platforms, such as CORE™ and Agile Audience Engine™, which are applicable to a multitude of industries. The company’s goal is to achieve return-on-investment driven results for clients. The firm uses data fusion and customized analytics to help clients manage risk, identify fraud and abuse, collect debts and acquire new customers.

In a news release, Derek Dubner, chief executive officer of Cogint, said, “We delivered a very strong quarter with revenues of $53 million, up 29% versus the second quarter of 2016, and adjusted EBITDA of $4.8 million, up 54%, driven by enterprise-wide adoption of our products and solutions. Given our innovative-driven product roadmap and the increasing momentum we experienced throughout the quarter, we are very optimistic about the second half of 2017.”

Key to the gains were a 39% jump in sales within information services, a 24% boost in performance marketing and revenue from its new Pay Per Call ad format, which was introduced in December 2016 and generated $1.5 million in additional sales in 2Q2017.

CORE™ is the company’s own next-generation data fusion platform, applicable to a variety of industries. These range from insurance and financial services companies to law enforcement, health care, law firms, government and others.

The Agile Audience Engine™ assists retailers, brands and marketers with customer identification on a massive scale. It targets consumers through personal identification information for the packaged goods, financial services and entertainment industries, among others. What helps make Cogint unique in this sector is its high 80% use of mobile devices for consumer interaction.

For more information, visit the company website at www.Cogint.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on August 15, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage:

SIGO 30.00% – News: Executes three year Lock-Up Agreement on over 90% of all outstanding shares

TBTC 20.00% – News: CasinoTrac© system approved for use in Nevada casinos

XPLR 18.78% – News: Partners with DCT Solutions

SYPR 12.50% – News: Posts Q2 2017 results

SSOK 11.11% – News: Concludes initial round of capital raising

LTRE 7.50% – News: Secures contract with the Texas Department of Information Resources

CDNA 6.43% – News: Participating in upcoming conferences

RKDA 6.17% – News: FDA approves SONOVA® GLA safflower oil in dog food

ATXI 6.11% – News: Names new VP of finance and corporate controller

TNDM 5.11% – News: Commences enrollment in pivotal trial for t:slim X2™ with PLGS

More from NetworkNewsBreaks

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsBreaks – SeeThruEquity Updates Coverage, Increases PT on Medical Transcription Billing, Corp. (NASDAQ: MTBC)

SeeThruEquity has updated its coverage and increased its price target to $4 on shares of Medical Transcription Billing, Corp.’s (NASDAQ: MTBC) stock. The company recently reported financial results for the second quarter of 2017, including a 49% increase in revenues, year-over-year. MTBC also reported a 55% increase for the first half of 2017, with revenues of approximately $16 million. The company attributes this growth primarily to its largest acquisition, MediGain, and a higher rate of retention from MediGain customers than originally expected.

For more information, visit www.mtbc.com

About Medical Transcription Billing, Corp.

MTBC is a healthcare information technology company that provides a fully integrated suite of proprietary web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The company’s integrated Software-as-a-Service (or SaaS) platform helps its customers increase revenues, streamline workflows and make better business and clinical decisions, while reducing administrative burdens and operating costs. MTBC’s common stock trades on the NASDAQ Capital Market under the ticker symbol “MTBC,” and its Series A Preferred Stock trades on the NASDAQ Capital Market under the ticker symbol “MTBCP.”

More from NetworkNewsBreaks

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsBreaks – Helios and Matheson Analytics, Inc. (NASDAQ: HMNY) Enters Agreement to Acquire Majority Stake in MoviePass™

Helios and Matheson Analytics (NASDAQ: HMNY) shares are up 5% mid-day on news that the company has entered into a definitive agreement to acquire a majority stake of movie subscription technology company MoviePass Inc. MoviePass is available in over 91% of all theaters in the U.S., and the app permits subscribers to see unlimited movies in theaters for a fee of $9.95 monthly. The closing of the transaction is subject to the company completing an equity or equity-linked financing transaction with gross proceeds of at least $10 million, among other material conditions. “With our big data and artificial intelligence platforms and other technologies that we own, we will be able to bring a significant technological advantage to MoviePass. Our mission at HMNY is to continuously be innovating, and this blending is a natural fit to take us up to the next level and beyond,” Helios and Matheson chairman and CEO Ted Farnsworth stated in the news release.

To view the full press release, visit: http://nnw.fm/V8YkJ

About Helios and Matheson

Helios and Matheson Analytics Inc. (NASDAQ: HMNY) is a provider of information technology services and solutions, offering a range of technology platforms focusing on big data, artificial intelligence, business intelligence, social listening, and consumer-centric technology. Its holdings include RedZone Map™, a safety and navigation app for iOS and Android users, a community-based ecosystem that features a socially empowered safety map app that enhances mobile GPS navigation using advanced proprietary technology. Through TrendIt, Helios and Matheson has acquired technology addressing crowd and migration patterns, and consumer behavior in real-time. The patented technology predicts population behavior, along with a crowd’s population size, origin and destination. HMNY is headquartered in New York, NY. For more information, visit www.hmny.com.

More from NetworkNewsBreaks

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com